| 41/51 | US=65 / Biol/Mol Frederiksen C, Lomholt AF, Nielsen HJ, Brünner N. TIMP-1 as a prognostic marker in colorectal cancer. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 679-96. ISBN 978-0-387-69056-8. |
| 42/51 | US=65 / Biol/Mol Jacobsen B, Kjaergaard M, Gardsvoll H, Ploug M. Structure and inhibition of the urokinase-type plasminogen activator receptor. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 699-719. ISBN 978-0-387-69056-8. ATIVADOR DO PLASMINOGENIO TIPO UROQUINASE; UPAR; ANTICORPOS MONOCLONAIS; ANTAGONISTAS PEPTIDICOS |
| 43/51 | US=65 / Biol/Mol Stoppelli MP, Andersen LM, Votta G, Andreasen PA. Engineered antagonists of uPA and PAI-1. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 721-58. ISBN 978-0-387-69056-8. UPA; PAI-1; ATIVACAO DO PLASMINOGENIO; DISSEMINACAO DO CANCER; PROPRIEDADES BIOQUIMICAS; ADESAO CELULAR; MIGRACAO CELULAR; INVASAO CELULAR; PROLIFERACAO CELULAR; SOBREVIVENCIA; APOPTOSE; ATIVIDADE ENZIMATICA |
| 44/51 | US=65 / Biol/Mol Fingleton B. MMP inhibitor clinical trials-the past, present, and future. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 759-85. ISBN 978-0-387-69056-8. |
| 45/51 | US=65 / Biol/Mol Nagase H, Murphy G. Tailoring TIMPs for selective metalloproteinase inhibition. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 787-810. ISBN 978-0-387-69056-8. TIMPS; INIBICAO SELETIVA DE METALOPROTEINASE; PROPRIEDADES BIOQUIMICAS |
| 46/51 | US=65 / Biol/Mol Yiotakis A, Dive V. Third-Generation MMP inhibitors: recent advances in the development of highly selective inhibitors. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 811-25. ISBN 978-0-387-69056-8. INIBIDORES DE MMP; GRUPOS DE LIGACAO DE ZINCO; FOSFINICOS; TRANSICAO ANALOGOS |
| 47/51 | US=65 / Biol/Mol Fields GB. Protease-activated delivery and imaging systems. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 827-51. ISBN 978-0-387-69056-8. PROTEASE; SISTEMAS DE IMAGEM; PRO-DROGAS; SISTEMA DE ENTREGA |
| 48/51 | US=65 / Biol/Mol Gill JH, Loadman PM. Development of tumour-selective and endoprotease-activated anticancer therapeutics. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 853-76. ISBN 978-0-387-69056-8. DESENVOLVIMENTO DE TUMORES SELETIVOS; ENDOPROTEASE ATIVADO; TERAPEUTICA ANTICANCER |
| 49/51 | US=65 / Biol/Mol Ala-aho R, Baker AH, Kähäri VM. Targeting degradome genes via engineered viral vectors. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 877-94. ISBN 978-0-387-69056-8. SEGMENTACAO GENES DEGRADOME; VETORES VIRAIS; VETORES RETROVIRAIS; VETORES DE ADENOVIRUS; VETORES DE VIRUS ADENO-ASSOCIADOS; BACULOVIRUS; HERPES SIMPLEX |
| 50/51 | US=65 / Biol/Mol Bugge TH. Physiological functions of plasminogen activation: effects of gene deficiencies in humans and mice. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 183-201. ISBN 978-0-387-69056-8. SISTEMA DE ATIVACAO DO PLASMINOGENIO; FUNCOES FISIOLOGICAS; DEFICIENCIAS GENETICAS; HUMANOS; RATOS; ALFA2-ANTIPLASMINA; PAI-1 |
| 51/51 | US=55 / Enfermagem Dealy C. Produtos para tratamento de feridas. In: Dealey C. Cuidando de feridas: um guia para as enfermeiras. 3 ed. São Paulo: Atheneu, 2008. p. 83-120. ISBN 85-7454-096-2. EVOLUCAO DOS CURATIVOS AO LONGO DOS TEMPOS; CURATIVOS. TECNICAS TRADICIONAIS; USO DE SOLUCOES NO TRATAMENTO DE FERIDAS; AMBIENTE EFICAZ PARA CICATRIZACAO; MODELADORES DE PROTEASES; FATORES DE CRESCIMENTO NO TRATAMENTO DAS FERIDAS; PRODUTOS A BASE DE ACIDO HIALURONICO; TERAPIA DE OXIGENIO HIPERBARICO; TERAPIA POR VACUO; CULTURA DE TECIDOS; ENGENHARIA DE TECIDOS; TERAPIA ALTERNATIVAS E TRATAMENTO DE FERIDAS |